FDA boxed warnings about hepatitis B virus (HBV) reactivation risk relate only to ofatumumab and rituximab. Eminent hepatologists say everyone destined for immunosuppression should be tested for HBV first.
Clinical remission is not necessarily good reason to stop treatment for rheumatoid arthritis. New MRI data show that many patients continue to show inflammation and osteitis, even if they no longer have symptoms.
Amgen has announced success in a Phase 3 trial of an adalimumab biosimilar. The subject of biosilimars is already "trending" in state legislatures, 10 of which now mandate notification of substitution.
An increase in the number of joints affected by psoriatic arthritis doesn't usually lead to changes in TNF blocker treatment, this retrospective study shows. But changes in discontinuation over time and by gender are puzzling.